Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder

被引:54
作者
Banaschewski, Tobias [1 ]
Soutullo, Cesar [2 ]
Lecendreux, Michel [3 ,4 ]
Johnson, Mats [5 ]
Zuddas, Alessandro [6 ]
Hodgkins, Paul [7 ]
Adeyi, Ben [7 ]
Squires, Liza A. [7 ]
Coghill, David [8 ]
机构
[1] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Child & Adolescent Psychiat & Psychotherapy, D-68072 Mannheim, Germany
[2] Univ Navarra Clin, Dept Psychiat & Med Psychol, Child & Adolescent Psychiat Unit, Pamplona, Spain
[3] Robert Debre Univ Hosp, Paediat Sleep Ctr, Paris, France
[4] Robert Debre Univ Hosp, Natl Reference Ctr Orphan Dis Narcolepsy Idiopath, Paris, France
[5] Queen Silvia Childrens Hosp, Child Neuropsychiat Unit, Gothenburg, Sweden
[6] Univ Cagliari, Dept Biomed Sci, Sect Neurosci & Clin Pharmacol, Cagliari, Italy
[7] Shire Dev LLC, Wayne, PA USA
[8] Univ Dundee, Div Neurosci, Dundee, Scotland
关键词
PARENT REPORT FORM; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; EFFICACY; ATOMOXETINE; EDITION; MEDICATIONS; SAFETY; MULTICENTER; RELIABILITY;
D O I
10.1007/s40263-013-0095-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD. The aim of this study was to assess HRQL and functional impairment outcomes in this clinical trial, using the Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) and the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P), respectively. Patients (aged 6-17 years) with diagnosed ADHD and a baseline ADHD Rating Scale IV total score a parts per thousand yen28 were randomized (1:1:1) to 7 weeks of double-blind treatment with once-daily LDX, placebo or the reference treatment, osmotic-release oral system methylphenidate (OROS-MPH). Participants' parents (or legally authorized representatives) completed the CHIP-CE:PRF and WFIRS-P questionnaires at baseline, at weeks 4 and 7, and/or at early termination. Endpoint was defined as the last on-treatment visit with valid data (a parts per thousand currency sign30 % missing items). The CHIP-CE:PRF Achievement domain was pre-specified as the primary HRQL outcome. The full analysis set comprised 317 patients (LDX, n = 104; placebo, n = 106; OROS-MPH, n = 107), the majority of whom completed the study (LDX, n = 77; placebo, n = 42; OROS-MPH, n = 72). Baseline CHIP-CE:PRF T-scores in four of the five domains were a parts per thousand yen1 standard deviation below norms (US community samples). Compared with placebo, LDX was associated with statistically significantly improved T-scores from baseline to endpoint in these four domains, with effect sizes of 1.280 (p < 0.001) in Achievement, 1.079 (p < 0.001) in Risk Avoidance, 0.421 (p < 0.01) in Resilience and 0.365 (p < 0.05) in Satisfaction. In LDX-treated patients, placebo-adjusted improvements from baseline to endpoint in WFIRS-P scores were statistically significant (p < 0.001) for total score and four of the six domains, with effect sizes of 0.924 (total score), 1.249 (Learning and School), 0.730 (Family), 0.643 (Social Activities) and 0.640 (Risky Activities). OROS-MPH treatment showed similar patterns of improvement from baseline to endpoint in both CHIP-CE:PRF and WFIRS-P scores. Baseline HRQL and functional impairment scores reflect the burden of untreated ADHD. The benefits of short-term stimulant treatment in children and adolescents with ADHD extend beyond symptomatic relief and impact positively on HRQL and daily functioning.
引用
收藏
页码:829 / 840
页数:12
相关论文
共 49 条
[1]   Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder [J].
Adler, Lenard A. ;
Goodman, David W. ;
Kollins, Scott H. ;
Weisler, Richard H. ;
Krishnan, Suma ;
Zhang, Yuxin ;
Biederman, Joseph .
JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (09) :1364-+
[2]  
[Anonymous], 2009, CHILD ADOL PSYCH MEN
[3]  
[Anonymous], EUR CHILD ADOLES S1
[4]  
[Anonymous], DIAGN MAN ADHD CHILD
[5]  
[Anonymous], MAN ATT DEF HYP DIS
[6]  
[Anonymous], LEITL DIAGN THER PSY
[7]  
[Anonymous], CAN ATT DEF HYP DIS
[8]  
[Anonymous], WEISS FUNCT IMP RAT
[9]  
[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
[10]   Advances in understanding and treating ADHD [J].
Antshel, Kevin M. ;
Hargrave, Teresa M. ;
Simonescu, Mihai ;
Kaul, Prashant ;
Hendricks, Kaitlin ;
Faraone, Stephen V. .
BMC MEDICINE, 2011, 9